QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.059535v1 308/2/419    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bao, A. Articles by Phillips, W. T. Search for Related Content PubMed PubMed Citation Articles by Bao, A. Articles by Phillips, W. T.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Direct ^99mTc Labeling of Pegylated Liposomal Doxorubicin (Doxil) for Pharmacokinetic and Non-Invasive Imaging Studies

Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas (A.B., B.G., R.K., W.T.P.); and Department of Chemistry, University of Texas at San Antonio, San Antonio, Texas (G.N.)

Pharmacokinetic and organ distribution studies of liposomal drugs in humans are a challenge. A direct labeling method using ^99mTc-N,N-bis(2-mercaptoethyl)-N',N'-diethyl-ethylenediamine (BMEDA) complex to label the commercially available pegylated liposomal doxorubicin, Doxil, has been introduced. Biodistributions of ^99mTc-Doxil in normal rats were performed to evaluate the feasibility of using it for monitoring the pharmacokinetics of liposomes encapsulating drugs. Labeling efficiency of ^99mTc-Doxil was 70.6 ± 0.8% (n = 3). In vitro incubation of ^99mTc-Doxil in 50% fetal bovine serum or 50% human serum at 37°C showed good labeling stability with 72.3 ± 3.6% or 78.6 ± 1.8% of activity associated with Doxil at 24 h, respectively (n = 3). There was a two-phase blood clearance with half-clearance times of 2.2 and 26.2 h after bolus intravenous injection in normal rats. Distribution of ^99mTc-Doxil at 44 h after injection had 19.8 ± 1.3% of injected dose in blood, 14.1 ± 1.7% in liver, 2.6 ± 0.3% in spleen, 9.0 ± 0.8% in bone with marrow, 6.0 ± 0.5% in skin, and 15.3 ± 4.3% in bowel (n = 5). Unencapsulated ^99mTc-BMEDA had a very rapid blood clearance with a half-clearance time of only 0.12 h (n = 4). By using this ^99mTc labeling method, biodistribution and pharmacokinetics of ammonium gradient liposomes encapsulating drugs can be determined by noninvasive scintigraphic imaging. This labeling method may be extended to ¹⁸⁶Re and ¹⁸⁸Re labeling to combine chemotherapy and radionuclide therapy for tumor treatment.

Address correspondence to: Dr. William T. Phillips, Department of Radiology, MSC 7800, UTHSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900. E-mail: phillips{at}uthscsa.edu

This article has been cited by other articles:

				M. M. Kleiter, D. Yu, L. A. Mohammadian, N. Niehaus, I. Spasojevic, L. Sanders, B. L. Viglianti, P. S. Yarmolenko, M. Hauck, N. A. Petry, et al. A Tracer Dose of Technetium-99m-Labeled Liposomes Can Estimate the Effect of Hyperthermia on Intratumoral Doxil Extravasation. Clin. Cancer Res., November 15, 2006; 12(22): 6800 - 6807. [Abstract] [Full Text] [PDF]

				J-H Chen, R Ling, Q Yao, Y Li, T Chen, Z Wang, and K-Z Li Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model Endocr. Relat. Cancer, March 1, 2005; 12(1): 93 - 100. [Abstract] [Full Text] [PDF]